Plain-English translation of NCT06550427 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →This trial is testing a new way to monitor lymphoma treatment using blood samples instead of radiation-based scans. Researchers will analyze DNA fragments from cancer cells in your blood to see how well your treatment is working and predict whether your lymphoma might come back. This test could become a safer alternative to traditional imaging scans.
Currently, doctors use CT and PET scans—which involve radiation exposure—to check whether lymphoma treatment is working. This trial exists to develop a safer blood test that can detect cancer DNA early and help predict treatment outcomes before cancer returns, especially for patients at high risk of their lymphoma coming back.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken at different points during your lymphoma treatment—likely before, during, and after chemotherapy. These samples are sent to a lab where scientists analyze the DNA from cancer cells in your blood using advanced genetic testing. You'll continue your regular cancer treatment as planned, and your participation involves providing these extra blood draws alongside your routine medical care.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Taiwan
National Taiwan University Hospital
Enrollment target
~200 participants
Started
August 2024
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tai-Chung Huang, Ph.D
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.